1. Benefit of endovascular thrombectomy for M2 middle cerebral artery occlusion in the ARISE II study
- Author
-
Tommy Andersson, Jeffrey L. Saver, Hormozd Bozorgchami, Marc Ribó, Heinrich Mattle, Osama O. Zaidat, Adam de Havenon, Aymeric Amelot, Ana Paula Narata, University of Utah, CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Service de Neurochirurgie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Department of Neurology [UCLA], University of California [Los Angeles] (UCLA), University of California-University of California-David Geffen School of Medicine [Los Angeles], University of California-University of California, Oregon Health and Science University [Portland] (OHSU), University of Bern, Vall d'Hebron University Hospital [Barcelona], Universitat Autònoma de Barcelona (UAB), Karolinska Institutet [Stockholm], C.A.Z. Groeninge, Bon Secours Mercy Health System [Toledo, OH, USA] (BSMHS), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Català de la Salut, [de Havenon A] Department of Neurology, University of Utah, Salt Lake City, Utah, USA. [Narata AP] Service of Radiology and Neuroradiology, University Hospital of Tours, Tours, France. [Amelot A] Department of Neurosurgery, CHU Tours, Tours, France. Hopital Universitaire Pitie Salpetriere, Paris, France. [Saver JL] Department of Neurology, UCLA, Los Angeles, California, USA. [Bozorgchami H] Oregon Health and Science University, Portland, Oregon, USA. [Mattle HP] Department of Neurology, Inselspital, University of Bern, Bern, Switzerland. [Ribo M] Unitat d’Ictus, Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Middle Cerebral Artery ,medicine.medical_treatment ,Logistic regression ,Brain Ischemia ,Vasos sanguinis - Cirurgia ,0302 clinical medicine ,Modified Rankin Scale ,Occlusion ,MESH: Thrombectomy ,angiography ,030212 general & internal medicine ,Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Cerebrovascular Disorders::Brain Ischemia::Brain Infarction::Cerebral Infarction::Infarction, Middle Cerebral Artery [DISEASES] ,Stroke ,MESH: Treatment Outcome ,Thrombectomy ,education.field_of_study ,medicine.diagnostic_test ,Endovascular Procedures ,Angiography ,MESH: Brain Ischemia ,MESH: Infarction, Middle Cerebral Artery ,Brain ,Infarction, Middle Cerebral Artery ,Infart cerebral - Imatgeria ,General Medicine ,stroke ,3. Good health ,Treatment Outcome ,thrombectomy ,Cardiology ,[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] ,medicine.medical_specialty ,enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::trastornos cerebrovasculares::isquemia cerebral::infarto encefálico::infarto cerebral::infarto de la arteria cerebral media [ENFERMEDADES] ,MESH: Endovascular Procedures ,brain ,Population ,610 Medicine & health ,[SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery ,Revascularization ,MESH: Stroke ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,Adverse effect ,education ,Other subheadings::Other subheadings::/diagnostic imaging [Other subheadings] ,Ischemic Stroke ,MESH: Humans ,business.industry ,Otros calificadores::Otros calificadores::/diagnóstico por imagen [Otros calificadores] ,MESH: Middle Cerebral Artery ,medicine.disease ,Surgery ,Neurology (clinical) ,Cateterisme intravascular ,business ,030217 neurology & neurosurgery - Abstract
BackgroundThe benefit of endovascular thrombectomy for acute ischemic stroke with M2 segment middle cerebral artery occlusion remains controversial, with uncertainty and paucity of data specific to this population.ObjectiveTo compare outcomes between M1 and M2 occlusions in the Analysis of Revascularization in Ischemic Stroke with EmboTrap (ARISE II) trial.MethodsWe performed a prespecified analysis of the ARISE II trial with the primary outcome of 90-day modified Rankin Scale score of 0–2, which we termed good outcome. Secondary outcomes included reperfusion rates and major adverse events. The primary predictor was M2 occlusion, which we compared with M1 occlusion.ResultsWe included 183 patients, of whom 126 (69%) had M1 occlusion and 57 (31%) had M2 occlusion. There was no difference in the reperfusion rates or adverse events between M2 and M1 occlusions. The rate of good outcome was not different in M2 versus M1 occlusions (70.2% vs 69.7%, p=0.946). In a logistic regression model adjusted for age, sex, and baseline National Institutes of Health Stroke Scale score, M2 occlusions did not have a significantly different odds of good outcome compared with M1 occlusions (OR 0.94, 95% CI 0.47 to 1.88, p=0.87).ConclusionIn ARISE II, M2 occlusions achieved a 70.2% rate of good outcome at 90 days, which is above published rates for untreated M2 occlusions and superior to prior reports of M2 occlusions treated with endovascular thrombectomy. We also report similar rates of good outcome, successful reperfusion, death, and other adverse events when comparing the M1 and M2 occlusions.
- Published
- 2020